Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 40Gastro-enteropancreatic neuroendocrine tumor 8Paraganglioma 6Pheochromocytoma 5Carcinoma, Neuroendocrine 4Carcinoid Tumor 3Neoplasms 2Stomach Neoplasms 1Somatostatin Receptor-positive Neuroendocrine Tumor 1Serotonin Syndrome 1Sarcoma, Synovial 1Recurrence 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Pancreatic Neoplasms 1Pancreatic Diseases 1Osteosarcoma 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Nerve Tissue 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Medulloblastoma 1Intestinal Neoplasms 1Intestinal Diseases 1Hypertension 1

Interventions

pasireotide 7Cabergoline 7Surgical Procedures, Operative 4Temozolomide 3Propofol 3Hydrocortisone 3Dexmedetomidine 3lanreotide 2Sevoflurane 2Saline Solution 2Rosiglitazone 2Radiotherapy 2Radiosurgery 2Proton Therapy 2Octreotide 2Human Growth Hormone 2Dexamethasone 2Desflurane 2Aminolevulinic Acid 2pegvisomant 1parecoxib 1lutetium Lu 177 dotatate 1loxoprofen 1farletuzumab 1entinostat 1corticorelin ovine 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Visual Field Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × lutetium Lu 177 dotatate × Endocrine × Clear all
NCT04106843 2020-09-07

Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSEndocrineHead & Neck

Paraganglioma, Parathyroid Neoplasms, Pheochromocytoma, Pituitary Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡